Movement Alert|CRISPR Therapeutics AG Intraday Decline 5.01%, valuation debate and recent earnings miss weigh on shares

Market Focus
11/12

On November 12, CRISPR Therapeutics AG fell 5.01% in Regular Trading, trading at $43.44 per share, with turnover of $18.8672 million.

The most recent market update tied the weakness to renewed valuation debate after recent clinical disclosures, alongside pressure from the company’s latest quarterly results. CRISPR Therapeutics AG previously reported September-quarter EPS of $1.15 loss, wider than the $0.98 loss expected by analysts, although revenue of $12.669 million exceeded estimates.

Recent pipeline news was constructive but did not prevent the selloff. On November 9, the company presented Phase 1b data for CTX310 showing mean reductions from baseline of 65% in circulating ANGPTL3 and 63% in triglycerides after a single-course treatment. Earlier, autoimmune data for zugo-cel also showed encouraging early responses. Even so, the latest market interpretation emphasized continuing losses and uncertainty around commercialization timing.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10